Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Average Recommendation of “Buy” by Brokerages

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have received an average recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and two have assigned a strong buy recommendation to the company.

Several analysts have issued reports on the company. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Zacks Research lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th.

Bayer Aktiengesellschaft Trading Up 0.3%

OTCMKTS:BAYRY opened at $10.56 on Friday. The company has a current ratio of 1.13, a quick ratio of 0.73 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $41.50 billion, a PE ratio of -117.32, a price-to-earnings-growth ratio of 5.27 and a beta of 0.69. The firm’s 50 day moving average is $8.92 and its 200 day moving average is $8.32. Bayer Aktiengesellschaft has a 12 month low of $4.80 and a 12 month high of $10.71.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.